Skip to Content

Viatris Inc VTRS Stock Quote

| Rating as of

NASDAQ:VTRS

Morningstar‘s Stock Analysis VTRS

There is no Morningstar’s Analysis data available.

Key Statistics VTRS

Company Profile VTRS

Business Description

Formed by the combination of Mylan and Pfizer’s Upjohn business in 2020, Viatris is one of the world’s largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company’s branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Contact
1000 Mylan Boulevard
Canonsburg, PA, 15317
T +1 724 514-1800
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 37,000

Related News VTRS